NGM·Healthcare·$1.9B·#25 / 520 in Healthcare
ANIP ANI Pharmaceuticals, Inc.
76SOLID
CATEGORY BREAKDOWN
GROWTH70
QUALITY89
STABILITY69
VALUATION94
GOVERNANCE63
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+43.8%
70
> 50% strong
Gross Margin
Revenue retained after direct costs
61.4%
87
> 50% strong
Cash Runway
Months of cash at current burn rate
999 months
100
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
114.1%
7
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.1x
94
< 3x strong
Rule of 40
Growth rate plus operating margin
53
93
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
7.4%
52
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.2%
87
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE ANIP WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when ANIP's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.